Galectin Therapeutics: Q4 Earnings Insights
Galectin Therapeutics (NASDAQ:GALT) reported its Q4 earnings results on Thursday, March 31, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Galectin Pharmaceuticals To Present 6 Scientific Abstracts At The Liver Meeting 2021, Hosted By AASLD
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it will present six scientific abstracts at The Liver Meeting™ 2021,
Galectin Therapeutics Q2 EPS $(0.15) Down From $(0.11) YoY
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.15) per share. This is a 36.36 percent decrease over losses of $(0.11) per share from the same period last year.
61 Biggest Movers From Yesterday
Gainers
Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program.
40 Stocks Moving In Monday’s Mid-Day Session
Gainers
Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million stock repurchase program.
64 Biggest Movers From Friday
Gainers
Sentage Holdings Inc. (NASDAQ: SNTG) shares surged 597.8% to settle at $34.89 on Friday as the company priced its IPO at $5 per share.